PulseAugur
EN
LIVE 22:19:21
中文(ZH) “昌郁医药”完成2.5亿元D轮融资

Changyu Medicine secures 250M RMB Series D funding for clinical trials

By PulseAugur Editorial · [1 sources] ·

Changyu Medicine has successfully closed a Series D funding round, securing 250 million RMB. The round was co-led by Yifeng Capital and Gaoteka Investment, with participation from Jiaxing Yuanfan and Real Capital Global. The funds will be allocated to advance the Phase III clinical trial of their lead product, XG005, for acute pain in the United States, and to support ongoing pipeline development and global expansion. AI

IMPACT Minimal direct AI industry impact; focuses on pharmaceutical development.

RANK_REASON Significant funding round for a pharmaceutical company. [lever_c_demoted from significant: ic=1 ai=0.1]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Changyu Medicine secures 250M RMB Series D funding for clinical trials

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
Significant funding round for a pharmaceutical company. [lever_c_demoted from significant: ic=1 ai=0.1]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
funding, product
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
60 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Changyu Medicine Completes 250 Million Yuan Series D Financing

    36氪获悉，据启点资本消息，“昌郁医药”宣布完成2.5亿元人民币D轮融资。本轮融资由倚锋资本、高特佳投资联合领投，另有嘉兴远帆、Real Capital Global等机构共同参与。启点资本连续担任财务顾问。本轮融资资金将主要用于昌郁医药首发产品XG005在美国开展Ⅲ期急性疼痛临床研究，并支持公司核心产品管线的持续开发及全球化推进。

RELATED TOPICS